Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING
JIB

Treatment with Fleeceflower Derivative Blocks Plaque Formation in Mouse Alzheimer's Disease Model

By BiotechDaily International staff writers
Posted on 26 Feb 2013
A compound derived from traditional Chinese herbal medicine prevented development of amyloid plaques when administered to young animals in a mouse model of Alzheimer's disease and reversed plaque formation when administered to older animals.

Investigators at the Capital Medical University (Beijing, China) worked with the APPV717I transgenic (Tg) mouse Alzheimer's disease model. In previous studies, these mice demonstrated cognitive impairments beginning at four months of age and developed amyloid plaques in the brain that were evident by 10 months.

In the current study Tg mice were treated with varying doses of tetrahydroxystilbene glucoside (TSG), the active compound derived from the Chinese herbal medicine tuber fleeceflower (Polygonum multiflorum Thunb). The drug was given to 4- or 10- month-old animals for a period of six months. At the end of the treatment, cDNA microarray analysis, reverse transcription PCR, western blotting, and immunochemical techniques were used to determine levels of alpha-synuclein messenger RNA (mRNA) and protein expression. Accumulation of alpha-synuclein leads to the formation of insoluble aggregates that have been implicated in several neurodegenerative diseases, including Parkinson's disease, dementia with Lewy bodies, and Alzheimer's disease.

Results published in the January 2013 issue of the journal Restorative Neurology and Neuroscience revealed that alpha-synuclein mRNA expression increased in the hippocampus of four-month to 16-month old Tg mice compared with age-matched non-Tg controls. Alpha-synuclein protein expression in the hippocampus also increased significantly in four-month to 16-month old Tg mice. Significant down-regulation of alpha-synuclein mRNA and protein expression in the hippocampus was found after treatment with TSG for six months in both 10- and 16-month-old Tg mice. Production of dimers and tetramers of alpha-synuclein protein in Tg mice was inhibited after treatment with TSG.

The expression and aggregation of alpha-synuclein increased in an age-dependent fashion in Tg mice. TSG not only prevented over-expression of alpha-synuclein at an early stage, but also reversed the increased expression of alpha-synuclein and inhibited aggregation at the late stage of Tg mice. Therefore, TSG may have potential to prevent and treat Alzheimer's disease.

"Our results raise the possibility that TSG might be a novel compound for the treatment of Alzheimer's disease and dementia with Lewy body," said first author Dr. Lan Zhang, associate professor of pharmacology at Capital Medical University. "The role of alpha-synuclein, especially in the early phase of Alzheimer's disease, and its interaction with amyloid-beta should be considered when developing new therapeutic strategies to target Alzheimer's disease."

Related Links:

Capital Medical University



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: This micrograph depicts the presence of aerobic Gram-negative Neisseria meningitidis diplococcal bacteria; magnification 1150x (Photo courtesy of the CDC - US Centers for Disease Control and Prevention).

Infection by Meningitis Bacteria Depends on Dimerization State of Certain Host Cell Proteins

A team of molecular microbiologists has untangled the complex three-way interaction between the non-integrin laminin receptor (LAMR1), galectin-3 (Gal-2), and the pathogenic bacterium Neisseria meningitidis.... Read more

Biochemistry

view channel

Discovery of Pain Receptor on T-cells Could Help Treat Autoimmune Disorders

Researchers have discovered that T-cells are activated by a pain receptor. The new findings revealed that the receptor helps control intestinal inflammation in mice and that its activity can be adjusted, providing a potential new target for treating certain autoimmune disorders, such as Crohn’s disease and possibly multiple... Read more

Lab Technologies

view channel
Image: Yale West Campus is organized into research institutes and core facilities — all designed to promote collaboration and interdisciplinary dialogue (Photo courtesy of Yale University).

American and European Partners Establish a Microscopy Center of Excellence

A prominent American university has announced a partnership agreement with a major European producer of microscopes and imaging tools that will establish a center for the use of cutting-edge imaging technologies... Read more

Business

view channel

Interest in Commercial Applications for Proteomics Continues to Grow

Increasing interest in the field of proteomics has led to a series of agreements between private proteomic companies and academic institutions as well as deals between pharmaceutical companies and novel proteomics innovator biotech companies. Proteomics is the study of the structure and function of proteins.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.